Severe allergic and eosinophilic asthma research hub

Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-label, controlled, randomized multinational pragmatic trial.

This study compares two existing asthma medications, omalizumab and mepolizumab, for people with severe allergic or eosinophilic asthma. It aims to see which treatment better prevents severe asthma attacks and how well each drug works overall in different groups of people.